For instance, in March 2017, Cancer Research U.K. completed its phase 1b clinical trial of (Modified Vaccinia Ankara) MVA-EBNA1/LMP2 vaccine. It is being treated on nasopharyngeal cancer patients with positive Epstein-Barr virus infection. Key Takeaways of the Global Monovaccine (Epstein-Barr Virus) Market:Currently, there is no approved monovaccines in any region. Furthermore, Asia Pacific is expected to be a potential region for nasopharyngeal cancer vaccine, as the prevalence of nasopharyngeal cancer is high in Asia Pacific. For instance, according to American Cancer Society, nasopharyngeal cancer is more common in several regions including South Asia, Middle East, and North Africa.

Source: The North Africa Journal August 18, 2020 13:41 UTC